Precision. Innovation. Remission.

At Tissue Immune Therapeutics GmbH , we are a dedicated team of scientists focused on advancing the treatment of autoimmune diseases. A spin-off from Prof. Andreas Ramming´s lab at the Friedrich-Alexander-University (FAU) Erlangen-Nürnberg, we leverage cutting-edge research to develop precision therapeutics that target the underlying mechanisms of these disorders.

With innovative validation techniques like single-cell RNA sequencing spatial transcriptomics, Imaging Flow/Mass Cytometry, high-resolution microscopy we maintain a robust approach to drug development. We validate new drug targets across various models—joint, tendon, lung, skin, kidney, and liver—ensuring our therapies are effective and safe. Our strong data science capabilities enable us to critically assess candidates efficiently, accelerating our path to clinical approval.

At Tissue Immune Therapeutics, we are committed to achieving remission for patients suffering from autoimmune diseases.

Our Passion

We are not only dedicated to developing new therapies; we are a passionate team that combines the highest scientific standards with innovative concepts. Our seamless network allows us to employ techniques tailored specifically to each challenge, ensuring we gather data with maximum efficiency.

Target Idendification

At TissueImmune, our Target Identification service is designed to pinpoint specific biological targets that play critical roles in autoimmune diseases. Utilizing advanced technologies and extensive expertise, we meticulously analyze cellular pathways and mechanisms to uncover novel therapeutic targets. Our innovative approach ensures a deep understanding of disease mechanisms, allowing us to provide tailored recommendations that drive effective drug development. Trust our dedicated team to guide you in identifying the most promising targets for your therapeutic strategies.

Drug Discovery

At TissueImmune, our Drug Discovery service transforms identified targets into viable therapeutic candidates through a comprehensive approach that integrates cutting-edge technologies and methodologies. Our expert team utilizes high-throughput screening, computational modeling, and sophisticated analytical tools to optimize drug candidates effectively. With a focus on precision and efficacy, we ensure that our discovery process is both efficient and thorough. By fostering collaborative partnerships, we aim to accelerate the journey from concept to clinic.

Candidate Validation

At TissueImmune, our Candidate Validation service employs innovative techniques, including scRNAseq and spatial transcriptomics, to rigorously assess drug candidates at various stages of development. Our experienced team utilizes advanced in vitro and in vivo models to scrutinize biological responses and drug mechanisms. By integrating high-resolution imaging and data analysis, we provide comprehensive insights that are critical for informed decision-making. Our robust approach allows to identify promising candidates and optimize their profiles for clinical advancement.

Key Publications & Partners

Rauber S, Mohammadian H, Schmidkonz C, Atzinger A, Soare A, ...Cañete JD, Schett G, Ramming A. CD200(+) fibroblasts form a pro-resolving mesenchymal network in arthritis. Nat Immunol. 2024. 10.1038/s41590-024-01774-4.

Wohlfahrt T, Rauber S, Uebe S, Luber M, Soare A, Ekici A, ...Distler O, Schett G, Distler JHW, Ramming A. PU.1 controls fibroblast polarization and tissue fibrosis. Nature. 2019. 10.1038/s41586-019-0896-x.

Rauber S, Luber M, Weber S, Maul L, Soare A, ...Pitzalis C, Neurath MF, McKenzie ANJ, Wirtz S, Schett G, Distler JHW, Ramming A. Resolution of inflammation by interleukin-9-producing type 2 innate lymphoid cells. Nat Med. 2017. 10.1038/nm.4373.